Study In Asthma Control
An Open-label, Multi-centre, Randomized, Parallel Group Clinical Effectiveness Study to Determine the Level of Asthma Control in Adolescent and Adult Patients With ADVAIR Versus Usual Care for 24 Weeks.
Sponsor: GlaxoSmithKline
Terminated
This trial was terminated. No reason was provided.
Listed as NCT00273026, this PHASE4 trial focuses on Asthma and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE4
-
Oct 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Apr 2018 [monthly]
Terminated PHASE4
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbotsford, Canada , Ajax, Canada , Barrie, Canada , Bay Roberts, Canada , Bolton, Canada , Brampton, Canada , Brandon, Canada , Brantford, Canada , Bridgewater, Canada , Brossard, Canada and 68 more locations